Omalizumab Treatment for Severe Uncontrolled Asthma

This study included 113 patients aged over 18 years and of Caucasian origin diagnosed with SUA according to GEMA 5.1 criteria, recruited in the Respiratory Medicine Department of the Hospital Universitario Virgen de las Nieves de Granada (Spain) between March 2007 and April 2022. Out of the 113 patients recruited, the response was evaluated in 110 patients treated with omalizumab, prior to beginning treatment and when 12 months had elapsed from the start of the biological therapy. The administration route of the drug was subcutaneous, with doses of 75 mg to 600 mg, depending on the initial IgE concentration and the patient’s weight, every 2 or 4 weeks [37 ]. The remaining patients did not meet the study’s evaluation criteria.